Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1994 1
1995 1
1996 1
2000 1
2001 1
2005 2
2007 1
2008 4
2011 2
2012 5
2013 3
2016 2
2018 1
2020 4
2021 9
2022 14
2023 4
2024 4
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Results by year

Filters applied: . Clear all
Page 1
Long-term Outcome of Risankizumab in Crohn's Disease: a Real-world GETAID Study.
Fumery M, Caron B, Hébuterne X, Altwegg R, Roblin X, Stefanescu C, Meyer A, Nachury M, Laharie D, Le Berre C, Guillo L, Biron A, Caillo L, Buisson A, Nancey S, Uzzan M, Vuitton L, Gilletta C, Geyl S, Blain A, Kirchgesner J, Ah-Soune P, Duveau N, Vidon M, Abitbol V, Paupard T, Tran-Minh ML, Defrance A, Peyrin-Biroulet L. Fumery M, et al. Among authors: guillo l. Clin Gastroenterol Hepatol. 2024 Dec;22(12):2451-2458.e1. doi: 10.1016/j.cgh.2024.04.016. Epub 2024 May 9. Clin Gastroenterol Hepatol. 2024. PMID: 38729389
Comparative effectiveness of tofacitinib versus upadacitinib for the treatment of acute severe ulcerative colitis.
Honap S, St-Pierre J, Colwill M, Patel K, Le Berre C, Caron B, Nogami A, Kobayashi T, Altwegg R, Laharie D, Hebuterne X, Nachury M, Roblin X, Uzzan M, Kotze PG, Lukáš M, Vieujean S, D'Amico F, Albshesh A, Guillo L, Fumery M, Nancey S, Ye BD, Bergemalm D, Halfvarson J, Buisson A, Karmiris K, Rubin DT, Vicaut E, Peyrin-Biroulet L; ATTRACT Study Group. Honap S, et al. Among authors: guillo l. Clin Gastroenterol Hepatol. 2025 Jul 26:S1542-3565(25)00639-1. doi: 10.1016/j.cgh.2025.07.025. Online ahead of print. Clin Gastroenterol Hepatol. 2025. PMID: 40721074 Free article.
Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study.
Osty M, Altwegg R, Serrero M, Benezech A, Lecomte A, Cadiot G, Vuitton L, Wampach A, Nancey S, Buisson A, le Berre C, Rouillon C, Gilletta C, Goutorbe F, Fumery M, Hammoudi N, Caillo L, Vidon M, Arab N, Sickersen G, Cavicchi M, Vieujean S, Charkaoui M, Richard N, Wils P, Caron B, Amiot A, Nuzzo A, Laharie D, Kirchgesner J, Uzzan M; GETAID‐J2J group. Osty M, et al. Aliment Pharmacol Ther. 2025 Aug;62(4):430-439. doi: 10.1111/apt.70199. Epub 2025 May 22. Aliment Pharmacol Ther. 2025. PMID: 40400411 Free PMC article.
Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases.
Guillo L, Abreu M, Panaccione R, Sandborn WJ, Azevedo VF, Gensler L, Moghaddam B, Ahuja V, Ali SA, Allez M, Ananthakrishnan AN, Bhattacharya A, Dubinsky M, Griffiths A, Hart A, Korelitz B, Kotze PG, Koutroubakis IE, Lakatos PL, Lindsay JO, Magro F, Mantzaris GJ, Ng SC, O'Morain C, Panés J, Parigi T, Ran Z, Rogler G, Rubin DT, Sachar DB, Siegmund B, Steinwurz F, Tysk C, Vavricka S, Verstraete SG, Brezin AP, Haemel AK, Dignass A, Sands BE, Danese S, Peyrin-Biroulet L. Guillo L, et al. Lancet Gastroenterol Hepatol. 2022 Mar;7(3):254-261. doi: 10.1016/S2468-1253(21)00297-1. Epub 2022 Jan 17. Lancet Gastroenterol Hepatol. 2022. PMID: 35051383
Higher Adalimumab Concentration Is Associated With Complete Fistula Healing in Patients With Perianal Fistulizing Crohn's Disease.
Papamichael K, Centritto A, Guillo L, Hier J, Sherman Z, Cheifetz AS; International Consortium of Therapeutic Drug Monitoring (Spectrum). Papamichael K, et al. Among authors: guillo l. Clin Gastroenterol Hepatol. 2024 Oct;22(10):2134-2136.e2. doi: 10.1016/j.cgh.2024.04.005. Epub 2024 Apr 29. Clin Gastroenterol Hepatol. 2024. PMID: 38692557
Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID.
Caron B, Seksik P, Buisson A, Wils P, Savoye G, Stefanescu C, Laharie D, Guillo L, Abitbol V, Bonnet J, Altwegg R, Vuitton L, Moussata D, Bourreille A, Biron A, Gilletta C, Fumery M, Nahon S, Nancey S, Camara H, Peyrin-Biroulet L. Caron B, et al. Among authors: guillo l. Therap Adv Gastroenterol. 2024 Aug 7;17:17562848241265776. doi: 10.1177/17562848241265776. eCollection 2024. Therap Adv Gastroenterol. 2024. PMID: 39119370 Free PMC article.
59 results